Rxivist logo

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation

By Nan Zhou, Alvaro Gutierrez Uzquiza, Xiang Yu Zheng, Dan Vogl, Alfred L. Garfall, Luca Bernabei, Anita Saraf, Laurence Florens, Michael P Washburn, Anuradha Illendula, John H Bushweller, Luca Busino

Posted 20 Sep 2018
bioRxiv DOI: 10.1101/423350 (published DOI: 10.1038/s41375-019-0403-2)

Ikaros family zinc finger protein 1 and 3 (IKZF1 and IKZF3) are transcription factors that promote multiple myeloma (MM) proliferation. The immunomodulatory imide drug (IMiD) lenalidomide promotes myeloma cell death via Cereblon (CRBN)-dependent ubiquitylation and proteasome-dependent degradation of IKZF1 and IKZF3. Although IMiDs have been used as first-line drugs for MM, the overall survival of refractory MM patients remains poor and demands the identification of novel agents to potentiate the therapeutic effect of IMiDs. Using an unbiased screen based on mass spectrometry, we identified the Runt-related transcription factor 1 and 3 (RUNX1 and RUNX3) as interactors of IKZF1 and IKZF3. Interaction with RUNX1 and RUNX3 inhibits CRBN-dependent binding, ubiquitylation and degradation of IKZF1 and IKZF3 upon lenalidomide treatment. Inhibition of RUNXs, via genetic ablation or a small molecule (AI-10-104), results in sensitization of myeloma cell lines and primary tumors to lenalidomide. Thus, RUNX inhibition represents a valuable therapeutic opportunity to potentiate IMiDs therapy for the treatment of multiple myeloma.

Download data

  • Downloaded 538 times
  • Download rankings, all-time:
    • Site-wide: 45,227
    • In cancer biology: 1,257
  • Year to date:
    • Site-wide: 104,755
  • Since beginning of last month:
    • Site-wide: 104,755

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide


Sign up for the Rxivist weekly newsletter! (Click here for more details.)